Author:
Ting Naitee,Chen Ding-Geng,Ho Shuyen,Cappelleri Joseph C.
Reference13 articles.
1. Dmitrienko, A., Wiens, B., & Westfall, P. (2006). Clinical trials. Journal of Biopharmaceutical Statistics, 16(5), 745–755.
2. Fricke, J., Varkalis, J., Zwillich, S., Adler, R., Forester, E., Recker, D. P., et al. (2002). Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. American Journal of Therapeutics, 9(2), 89–97.
3. Hamlett, A., Ting, N., Hanumara, C., & Finman, J. S. (2002). Dose spacing in early dose response clinical trial designs. Drug Information Journal, 36(4), 855–864.
4. ICH E9 Statistical Principles for Clinical Trials. (1998). International conference on harmonization—Harmonized Tripartite Guideline.
5. Mallinckrodt, C. H., Lane, P. W., Schnell, D., Peng, Y., & Mancuso, J. P. (2008). Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Information Journal, 42, 303–319.